Investigator Initiated Trials (IIT's):

Ausgewählte IIT's

Neue Erkenntnisse zu pleiotropen Effekten von Stoffwechselpharmaka:

DIS: Diabetesinterventionsstudie.
RIAD-Studie: Risk factors in IGT for Atherosclerosis and Diabetes.
PIOSTAT: Pioglitazone and Statin in high cardiovascular risk patients.
DIG: Diabetes in Germany study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice.
AIDA: The Acarbose action on low grade Inflammation and Immune response in type 2 Diabetes on Atherosclerosis risk study.
Glory: Comparative investigation of efficacy and safety of Insuline glargine versus Metformin as first line drug in treatment of early Type 2 Diabetes.
PIOComb: Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy.
ORIGIN-Substudy: Outcome Reduction with Initial Glargine Intervention.
Metabolisches Syndrom: Gemeinsames Projekt mit der Stiftung Rufzeichen Gesundheit
IMT-München: Glycemic variability and Intima Media Thickness in different stages of glucose tolerance.